vetmedin 1.25 mg chewable tablets for dogs
boehringer ingelheim animal health australia pty. ltd. - pimobendan - oral bolus, chewable - pimobendan pyridazinone active 1.25 mg/tb - cardiovascular system - dog | bitch | castrate | puppy - congestive heart failure | dilated cardiomyopathy | mitral and/or tricuspid regur | valvular insufficiency
pimobendan- pimobendan powder
attix pharmaceuticals - pimobendan (unii: 34ap3bbp9t) (pimobendan - unii:34ap3bbp9t) -
vetmedin 1.25 mg chewable tablets for dogs
boehringer ingelheim ltd - pimobendan - tablets chewable - 1.25 mg/tablet - pimobendane - canine - cardiovascular
vetmedin chew 1.25 mg chewable tablets for dogs
boehringer ingelheim ltd - pimobendan - tablets chewable - 1.25 mg/tablet - pimobendane - canine - cardiovascular
vetmedin 1.25 mg capsules for dogs
boehringer ingelheim animal health new zealand limited - pimobendan - pimobendan 12.5 g/kg - cardiovascular agent
vetmedin 1.25mg chewable tablets for dogs
boehringer ingelheim animal health new zealand limited - pimobendan - pimobendan 2.5 g/kg - cardiovascular agent
cormedin 1.25 mg tablets for dogs
zoetis new zealand limited - pimobendan - pimobendan 5.53 g/kg - cardiovascular agent
cardisan 1.25 mg chewable tablets for dogs
alfasan nederland b.v - pimobendan - chewable tablet - pimobendan
vetmedin® chew vetmedin chew 1.25 mg chewable tablets for dogs vetmedin chew 5 mg chewable tablets for dogs vetmedin chew 10
boehringer ingelheim animal health usa inc. - pimobendan (unii: 34ap3bbp9t) (pimobendan - unii:34ap3bbp9t) - for the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation). (see also section “dosage, routes and method of administration”). for the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter) in doberman pinschers following echocardiographic diagnosis of cardiac disease (see section “special warnings” and “precautions for use in animals”). for the treatment of dogs with myxomatous mitral valve disease (mmvd) in the preclinical stage (asymptomatic with a systolic mitral murmur and evidence of increased heart size) to delay the onset of clinical symptoms of heart failure (see section “special warnings” and “special precautions for use in animals”). do not use pimobendan in hypertrophic cardiomyopathies or in diseases in which an improvement in cardiac output cannot be achieved for functional or anatomical re
vetmedin® 1.25, 2.5, 5.0 mg pimobendan capsules for dogs
boehringer ingelheim animal health usa inc. - pimobendan (unii: 34ap3bbp9t) (pimobendan - unii:34ap3bbp9t) - 1. for the treatment of congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency. it is recommended that the diagnosis of congestive heart failure be confirmed by radiographs or diuretic responsiveness. treatment should be initiated only in symptomatic cases which will benefit from increased myocardial contractility (positive inotropy). 2. to delay the time of onset of congestive heart failure or sudden death in doberman pinscher dogs with clinically asymptomatic dilated cardiomyopathy. clinically asymptomatic dilated cardiomyopathy is characterized by an increase in left ventricular end-systolic and end-diastolic diameter and should be diagnosed by means of a comprehensive cardiac examination (including echocardiographic examination and possibly holter monitoring). vetmedin® capsules should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic ste